CCTG has opened the anticipated international brain cancer study CCTG CE9 (LUMOS2) - joining forces with the Australian Cooperative Trials Group for Neuro-Oncology (COGNO) to make enrollment accessible to Canadian patients.
Radiotherapy to Block (CURB2) Oligoprogression In Metastatic Non-Small-Cell Lung Cancer
STRIDE (durvalumab + tremelimumab) with Lenvatinib vs STRIDE Alone in Patients with Unresectable Hepatocellular Carcinoma (SLIDE-HCC)
LND101 for Fecal Microbiota Transplantation in Combination with Immune Checkpoint Blockade in Patients with Advanced Melanoma
Addition of Docetaxel to Androgen Receptor Pathway Inhibitors in Patients with Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response (TRIPLE-SWITCH)
The CCTG ES3 NEEDS international esophageal cancer clinical trial is now opened in Canada. The study is investigating whether delaying surgery for patients with squamous cell carcinoma of the esophagus is as good as the current treatment.
Eradicating MRD in Patients with AML prior to Stem Cell Transplant (ERASE)
VIGOR: Vorasidenib as Maintenance Treatment after First-line Chemoradiotherapy in IDH-mutant Grade 2 or 3 Astrocytoma
CO33: Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Advanced, Colorectal Adenocarcinoma: The BATTMAN Trial
Delayed Reduced Volume and Dose Elective Ratiotherapy (REVERT) in Patients with HNSCC
CALMS: Combination Therapy with Luspatercept in Lower Risk MDS CTEP approval: 2024AUG27 (date of US Steering Committee Evaluation)
Congratulations to the PR19 Team from the Odette Cancer Centre at Sunnybrook for being recognized with the Phase III Team Award for CCTG-Led Trials.
CCTG is very pleased to present the Joseph Pater Founder’s Award for Excellence in Clinical Trials Research to Dr. Jolie Ringash, a radiation oncologist at the University of Toronto. The award is presented yearly at the Spring Meeting to a clinical trials research investigator whose leadership and body of work has contributed to significant advances in the understanding, diagnosis, treatment, cure, and prevention of cancer.
CCTG former Directors joint statement regarding US requirements for identity proofing and multi-factor authentication
Congratulations to Dr. Ali Hosni Abdalaty from Princess Margaret Cancer Centre (UHN) for his Ralph Meyer Phase III Program Young Investigator Award received at the CCTG Spring Meeting.
CCTG IND243: A Phase II Study of RP-6306 in Patients with Advanced Cancer has been centrally activated.
This study is being done to answer the following questions:
New this year at the CCTG Spring Meeting is an open workshop and education session on engaging patient representatives in CCTG clinical trials. This accredited workshop takes place on Friday 28 at 10:30 in the Wren room at the Chelsea Hotel.
Participants are invited to discuss and assess the Investigator and Patient perspective in patient-centred clinical trials. There will be an exploration of the CCTG Patient Engagement Model and an assessment of the clinical trial lifecycle identifying touch points to engage patients.
To ensure the security and safety of National Cancer Institute (NCI) systems, subjects, research staff, and all associated sensitive information, NCI introduced an identity verification system to access to the Cancer Therapy Evaluation Program (CTEP) and the Cancer Trails Support Unit (CTSU) websites in accordance with the Federal Information Security Management Act(FISMA) in July 2022. This new process uses ID.me, and requires completion of Identity Proofing (IP) and establishment of a Multi Factor Authentication (MFA) method as part of the registration process.
Request an invitation portal: closes April 17th
Online Registration: closes April 19th
On-site Registration: Beat the Friday morning line-up and register on Thursday!!
